Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  The Lancet

• Publication date

  2018-03-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(18)30136-3PMID 29395273
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome

  2018cited by this paper
• Molecular Pharmacology of Phytocannabinoids.

  2017cited by this paper
• Dosing considerations for rufinamide in patients with Lennox-Gastaut syndrome: Phase III trial results and real-world clinical data.

  2017cited by this paper
• Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers.

  2017cited by this paper
• Trial of Cannabidiol for Drug‐Resistant Seizures in the Dravet Syndrome

  2017cited by this paper
• Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.

  2017cited by this paper
• Thirty Years of Orphan Drug Legislation and the Development of Drugs to Treat Rare Seizure Conditions: A Cross Sectional Analysis

  2016cited by this paper
• Cannabidiol and Epilepsy: Sifting, Winnowing and Buzz

  2016cited by this paper
• Molecular Targets of Cannabidiol in Neurological Disorders

  2015cited by this paper
• Drug–drug interaction between clobazam and cannabidiol in children with refractory epilepsy

  2015cited by this paper
• Nonpharmacologic care for patients with Lennox‐Gastaut syndrome: Ketogenic diets and vagus nerve stimulation

  2014cited by this paper
• Lennox‐Gastaut syndrome: A consensus approach to differential diagnosis

  2014cited by this paper
• The efficacy and tolerability of pharmacologic treatment options for Lennox‐Gastaut syndrome

  2014cited by this paper
• Surgical options for patients with Lennox‐Gastaut syndrome

  2014cited by this paper
• Experience in the use of clobazam in the treatment of Lennox–Gastaut syndrome

  2014cited by this paper
• Vagus nerve stimulation vs. corpus callosotomy in the treatment of Lennox-Gastaut syndrome: a meta-analysis.

  2013cited by this paper
• Treatment of Lennox-Gastaut syndrome.

  2013cited by this paper
• Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome

  2011cited by this paper
• Vagus nerve stimulation: effectiveness and tolerability in 64 paediatric patients with refractory epilepsies

  2011cited by this paper
• Increased Risk of Death Among Children With Lennox-Gastaut Syndrome and Infantile Spasms

  2010cited by this paper
• Cannabidiol Displays Antiepileptiform and Antiseizure Properties In Vitro and In Vivo

  2010cited by this paper
• Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology.

  2009cited by this paper
• Treatment of Lennox-Gastaut syndrome: overview and recent findings

  2008cited by this paper
• Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome

  2008cited by this paper
• Epilepsy in Children in Navarre, Spain: Epileptic Seizure Types and Epileptic Syndromes

  2007cited by this paper
• Efficacy and Safety of the Ketogenic Diet for Intractable Childhood Epilepsy: Korean Multicentric Experience

  2005cited by this paper
• Treatment of Lennox-Gastaut syndrome.

  2003cited by this paper
• Prevalence and Descriptive Epidemiology of Lennox‐Gastaut Syndrome Among Atlanta Children

  1997cited by this paper

• Cannabinoids and drug-drug pharmacokinetic interactions: Deciphering the risks.

  2026cites this paper
• Flexibility in the Modelling of Comparative Effectiveness in the Absence of Head-to-Head Comparisons in the NICE Single Technology Appraisal of Fenfluramine for Treating Seizures Associated with Lennox-Gastaut Syndrome: An External Assessment Group Perspective.

  2026cites this paper
• A CBD-rich hemp extract is superior to CBD alone in reducing relapse to methamphetamine-seeking in rats.

  2026cites this paper
• Safety of cannabidiol versus placebo in healthy population: a systematic review and meta-analysis.

  2026cites this paper
• Cannabidiol in Neurology: Current Insights and Translational Perspectives.

  2026cites this paper
• A systematic review of highly purified cannabidiol in developmental and epileptic encephalopathies and complex treatment-resistant epilepsies: Changes in seizure frequency and adverse events.

  2026cites this paper
• Long-Term Evaluation of Cannabidiol in Pediatric Drug-Resistant Epilepsy: A Real-Time Single-Center Retrospective Study

  2026cites this paper
• A temporary spike: Investigating Lennox-Gastaut syndrome incidence in the US following FDA approval of cannabidiol.

  2026cites this paper
• Antiseizure Effects of Cannabidiol in Combination With Cannabigerol in the Maximal Electroshock Seizure Model

  2026cites this paper
• Cannabidiol potentiates p53-driven autophagic cell death in non-small cell lung cancer following DNA damage: a novel synergistic approach beyond canonical pathways

  2025cites this paper
• Pharmacological and Pharmacokinetic Profile of Cannabidiol in Human Epilepsy: A Review of Metabolism, Therapeutic Drug Monitoring, and Interactions with Antiseizure Medications

  2025cites this paper
• Safety and efficacy of vigabatrin add on compared to placebo in Lennox-Gastaut syndrome (LennoVig): A single center randomized double-blind placebo-controlled trial.

  2025cites this paper
• Caregiver-reported non-seizure and seizure outcomes with cannabidiol and clobazam in patients aged ≥2 years with Lennox-Gastaut syndrome or Dravet syndrome: A subgroup analysis of the BECOME survey.

  2025cites this paper
• Retrospective Multicenter Chart Review Study of Adjunctive Cannabidiol for Seizures Associated with Lennox–Gastaut Syndrome, Dravet Syndrome and Tuberous Sclerosis Complex

  2025cites this paper
• Effectiveness and safety of cenobamate in Lennox-Gastaut syndrome: A multicenter real-world study in Spain.

  2025cites this paper
• Understanding the role of oxylipins in Cannabis to enhance cannabinoid production

  2025cites this paper
• EEG functional connectivity as a marker of evolution from infantile epileptic spasms syndrome to Lennox–Gastaut syndrome

  2025cites this paper
• Cannabidiol - a friend or a foe?

  2025cites this paper
• A 13-week oral toxicity and toxicokinetic study of cannabidiol in Sprague Dawley rats with a 4-week recovery period

  2025cites this paper
• Impact of long-term treatment with cenobamate on concomitant usage of antiseizure medications: A real-world retrospective study in Spain.

  2025cites this paper
• Estudio de vida real con cannabidiol farmacéutico en epilepsia resistente

  2025cites this paper
• The Anticonvulsant Effects of Different Cannabis Extracts in a Zebrafish Model of Epilepsy

  2025cites this paper
• Use of cannabidiol for off-label treatment of patients with refractory focal, genetic generalised and other epilepsies

  2025cites this paper
• Cannabidiol potentiates phenobarbital effects in the control of pentylenetetrazole (PTZ)-induced epileptic seizures in neonate rats

  2025cites this paper
• The Therapeutic Potential of Cannabidiol in Skin Conditions

  2025cites this paper
• History of lennox-gastaut syndrome: Sixty years of advancements in therapeutic practices.

  2025cites this paper
• Current and emerging pharmacotherapies in Lennox-Gastaut syndrome

  2025cites this paper
• Increased seizure frequency graphs in medication trials: FDA labels vs. peer-review.

  2025cites this paper
• Exploring the interconnected properties of cannabidiol suspensions and orodispersible films

  2025cites this paper
• Cannabidiol Potentiates Phenobarbital-Induced Cell Death in the Developing Brain.

  2025cites this paper
• Influence of Cannabidiol Use on Visual Function and Optical Quality: A Randomized Controlled Trial

  2025cites this paper
• Adult hippocampal neurogenesis and temporal lobe epilepsy: A potential key to understanding cognitive deficit.

  2025cites this paper
• A Holistic Review of Cannabis and Its Potential Risks and Benefits in Mental Health

  2025cites this paper
• Treatment of epilepsy using newer antiseizure medications: A retrospective cohort study of prescription patterns in Sweden 2013–2022

  2025cites this paper
• Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.

  2025cites this paper
• Recent Advances in the Management of Seizures in Children

  2025influential citation
• Doctors’ and pharmacists’ perspectives on the clinical use of medicinal Cannabis: a cross-sectional study

  2025cites this paper
• Medicinal cannabinoid use and the risk of developing psychoses and suicidality

  2025cites this paper
• A multicenter cohort study on the efficacy, retention, and tolerability of cenobamate in patients with developmental and epileptic encephalopathies

  2025cites this paper
• Cannabidiol abrogates cue-induced anxiety associated with normalization of mitochondria-specific transcripts and linoleic acid in the nucleus accumbens shell

  2025cites this paper
• Cannabidiol for treatment of irritability and aggressive behavior in children and adolescents with autism spectrum disorder: background and methods of the cannabidiol study in children with autism spectrum disorder study

  2025cites this paper
• Update on Antiseizure Medications 2025

  2025cites this paper
• Optimising Cannabidiol Delivery: Improving Water Solubility and Permeability Through Phospholipid Complexation

  2025cites this paper
• Expanding the therapeutic role of highly purified cannabidiol in monogenic epilepsies: A multicenter real‐world study

  2025cites this paper
• Adjunctive use of cannabidiol in pediatric drug-resistant epilepsy: A retrospective multicenter analysis.

  2025cites this paper
• Appropriate selection of participants in pediatric developmental and epileptic encephalopathy trials: Lessons learned and future opportunities

  2025cites this paper
• Seizure-type-specific treatment responses in Lennox-Gastaut Syndrome: A comprehensive review of pharmacological, neuromodulatory, dietary, and surgical therapies.

  2025cites this paper
• Psychiatric and behavioural side effects of antiseizure medications in epilepsy

  2025cites this paper
• [Low Abuse Potential of Plant-Derived Highly Purified Cannabidiol: A Narrative Review].

  2025cites this paper
• PHARMACOLOGICAL CHARACTERIZATION OF A NEW SYNTHESIS COMPOUND WITH ANTAGONISTIC ACTION ON CB1 RECEPTORS: EVIDENCE FROM THE ANIMAL EXPERIMENTAL MODEL.

  2025cites this paper
• Efficacy and safety of cannabidiol in a single-center pediatric drug-resistant epilepsy cohort: a retrospective study

  2025cites this paper
• Hepatotoxicity evaluation of cannabidiol, cannabinol, cannabichromene and cannabigerol using a human quad culture liver chip

  2025cites this paper
• Practical approach to the safe use of cannabidiol in patients with refractory epilepsy: a mini review

  2025cites this paper
• Clinical practice guidelines for the administration of third-generation anti-seizure medications.

  2025cites this paper
• Cannabidiol exerts antiinflammatory effects but maintains T effector memory cell differentiation in humans

  2025cites this paper
• A multicenter study on the use of purified cannabidiol for children with treatment-resistant developmental and epileptic encephalopathies.

  2025cites this paper
• Cannabinoids for Medical Purposes in Children: A Living Systematic Review

  2025influential citation
• Cannabidiol ameliorates seizures and neuronal damage in ferric chloride-induced posttraumatic epilepsy by targeting TRPV1 channel.

  2025cites this paper
• Use of Medicinal Cannabis for Epilepsy in the Australian Community 2023–2024: A Cross-Sectional Survey

  2025influential citation
• Caregiver experiences of children living with a diagnosed neurological disability and using medical cannabis.

  2025cites this paper
• A 1:1 combination of cannabidiol and Δ9-tetrahydrocannabinol inhibit toll-like receptor 7- and 8-mediated inflammation in human immune cells.

  2025cites this paper
• Medical Cannabis Library: development of a curated database for research articles on cannabis therapeutic activity

  2025cites this paper
• 19 patients report seizure freedom with medical cannabis oil treatment for drug-resistant epilepsy: a case series

  2025cites this paper
• The Role of the Endocannabinoid System in the Mechanism of Action of Nonopioid Analgesics.

  2025cites this paper
• Long‐term efficacy and safety of cannabidiol in patients with treatment‐resistant focal epilepsies treated in the Expanded Access Program

  2025cites this paper
• BRIDGING THE GAP BETWEEN SEIZURE CONTROL AND QUALITY OF LIFE: STIRIPENTOL AND FENFLURAMINE IN DRAVET SYNDROME

  2025cites this paper
• Cannabidiol exerts anti-inflammatory effects but maintains T effector memory cell differentiation: A Single-Cell Study in Humans

  2025cites this paper
• Clinically Meaningful Reduction in Drop Seizures in Patients with Lennox–Gastaut Syndrome Treated with Cannabidiol: Post Hoc Analysis of Phase 3 Clinical Trials

  2025influential citation
• Under the Influence: Cognitive Effects of Medical Marijuana on Developing Minds.

  2025cites this paper
• Acute cannabidiol (CBD), tetrahydrocannabinol (THC) and their mixture (THC:CBD) exert differential effects on brain activity and blood flow in rats: A translational neuroimaging study.

  2025cites this paper
• Analysis of the cannabidiol effects in epilepsy treatment based on seizure characteristics in EEG recordings - A review.

  2025cites this paper
• Epileptic drop attacks: More than just atonic seizures.

  2025cites this paper
• Cannabidiol combined with GABAergic drugs but not with sodium channel blockers prevents the development of drug-resistance seizures in a preclinical model

  2025cites this paper
• Molecular targets of cannabinoids and their derivatives in epilepsy – a review with focus on CBD

  2025cites this paper
• Efficacy and safety of cannabidiol in children with developmental and epileptic encephalopathies: A systematic review.

  2025cites this paper
• Exploring the therapeutic potential of Cannabidiol in soft tissue wound healing: Delivery strategies and anti-inflammatory pathways

  2025cites this paper
• Beyond the hype - who uses cannabidiol for self-medication – and why: a cross-sectional study in Germany

  2025cites this paper
• The Cannabinoid System as a Potential Novel Target for Alcohol‐Associated Liver Disease: A Propensity‐Matched Cohort Study

  2025cites this paper
• Treatment of Seizures in People with Intellectual Disability

  2025cites this paper
• Treatment With Full‐Spectrum Cannabidiol Oil Improved the Pathological Findings of Dystrophic Mutant Mice

  2025cites this paper
• CBD and the 5-HT1A receptor: A medicinal and pharmacological review.

  2025cites this paper
• Assessing the Neuroprotective Benefits of Cannabis Sativa in Epilepsy Management

  2025cites this paper
• Cognitive and behavioral impact of antiseizure medications, neuromodulation, ketogenic diet, and surgery in lennox-gastaut syndrome: A comprehensive review.

  2025cites this paper
• Antiseizure medications for Lennox-Gastaut Syndrome: Comprehensive review and proposed consensus treatment algorithm.

  2025cites this paper
• Cannabidiol in Foods and Food Supplements: Evaluation of Health Risks and Health Claims

  2025cites this paper
• Investigation in blood-brain barrier integrity and susceptibility to immune cell penetration in a mouse model of Dravet syndrome

  2025cites this paper
• Efficacy and safety of pharmacological and non-pharmacological therapies in Lennox-Gastaut syndrome: a systematic review and network meta-analysis

  2025cites this paper
• Value of cannabidiol as adjunctive treatment for Lennox Gastaut syndrome: cost-effectiveness and budget impact analysis

  2025influential citation
• The efficacy of cannabidiol for seizures reduction in pharmacoresistant epilepsy: a systematic review and meta-analysis

  2025cites this paper
• Cannabinoid Use in Pediatric Epilepsy

  2025influential citation
• Cannabis derivatives and their synthetic analogs for treatment-resistant epilepsy: A systematic review and meta-analysis.

  2025cites this paper
• New Pharmacological Therapies in the Treatment of Epilepsy in the Pediatric Population

  2024cites this paper
• TRPV1 channel in the pathophysiology of epilepsy and its potential as a molecular target for the development of new antiseizure drug candidates.

  2024cites this paper
• Effects of Cannabidiol on Social Relating, Anxiety, and Parental Stress in Autistic Children: A Randomized Controlled Crossover Trial

  2024cites this paper
• Medical cannabis for children: Evidence and recommendations.

  2024cites this paper
• Les données probantes et les recommandations sur le cannabis à des fins médicales chez les enfants.

  2024cites this paper
• Trends in U.S. Medical Cannabis Registrations, Authorizing Clinicians, and Reasons for Use From 2020 to 2022

  2024cites this paper
• Effect of Hepatic Impairment on the Pharmacokinetics of Fenfluramine and Norfenfluramine

  2024cites this paper
• Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders

  2024cites this paper
• Effects of cannabidiol on psychosocial stress, situational anxiety and nausea in a virtual reality environment: a protocol for a single-centre randomised clinical trial

  2024cites this paper